Summary

Dr. Susan Bates received her M.D. degree from the University of Arkansas School of Medicine. She completed her clinical training in internal medicine at Georgetown University in Washington, D.C., and in medical oncology at the National Cancer Institute (NCI) in Bethesda, MD. Dr. Bates was a Lead Clinical Investigator and Head of the Molecular Therapeutics Section in the Developmental Therapeutics Branch of the Center for Cancer Research before moving to Columbia University in August 2015. During her years at the NCI, Dr. Bates led a highly successful translational research program focused on mechanisms of multidrug resistance and approaches to evaluate and improve the activity of epigenetic modifying agents. Her laboratory was among the first to clone the multidrug transporter ABCG2, eventually characterizing its function and its role in chemo-resistance and chemo-protection. This effort built upon earlier work elaborating the role of the multi-drug transporter P-glycoprotein that had defined the drug sensitivity profiles of cell lines in vitro, particularly in the NCI-60 cell line panel. The latter observation continues to impact how the NCI-60 cell line panel is used in drug discovery, and helped her identify a novel agent, at that time known as depsipeptide. Dr. Bates brought this drug to the clinic and after completing its phase I testing, served as Principal Investigator of a multi-institutional, international Phase II study of romidepsin (depsipeptide) in cutaneous and peripheral T-cell lymphoma. Working with Gloucester Pharmaceuticals, the data from this study were included in New Drug Applications (NDA) to the U.S. Food & Drug Administration (FDA). This partnership led to approval by the FDA of romidepsin for two indications - initially for cutaneous T-cell lymphoma and later for peripheral T-cell lymphoma. Dr. Bates' current interests are both laboratory and clinical in nature. Her laboratory efforts include laboratory and translational studies on drug resistance in T-cell lymphomas and advanced solid tumors including breast, pancreatic, neuroendocrine, renal and lung cancers. Her work is dedicated to new drug development, and finding antineoplastic agents that, alone or in combination with other anticancer agents, improve the options available for difficult to treat cancers. Emanating from the clinical and translational development of romidepsin, a histone deacetylase (HDAC) inhibitor, a current focus is on epigenetic therapies, and the development of combination therapies to use with HDAC inhibitors in refractory advanced cancers, including solid tumors. She also has a special interest in drug delivery and drug distribution and the role of the blood brain barrier in creating a sanctuary site for cancers that metastasize to the brain. Clinically, her goal has always been to translate ideas from the laboratory to clinical trials, an effort that has proven very successful. Clinically she seeks to develop combination therapies with histone deacetylase inhibitors for the therapy of solid tumors; and to develop therapies to treat central nervous system metastases, a complication of cancer that is becoming a greater problem as patients live longer with cancer.
Read More Read less

Office Location

CUIMC/Herbert Irving Pavilion

161 Fort Washington Ave # 9New York, NY 10032

Quick Facts

  • accepting new patients
  • 3.8
  • 48 years of experience
  • 21 insurance plans accepted
  • speaks Spanish, English
  • University Of Arkansas For Medical Sciences College Of Medicine
  • 6 written reviews
  • 3 specialties
  • 14 areas of expertise
  • 2 board certifications
  • 1 hospital affiliation
  • 1 office location
  • Female

Patients’ Perspective

  • Gave an accurate diagnosis
  • Had a good bedside manner
  • Spent time with me

Insurance Plans Accepted by Dr. Susan E. Bates

  • Accepts Medicare
  • Accepts Medicaid
  • Aetna
  • Affinity Health Plan
  • Amida Care
  • Cigna
  • ElderServe
  • Emblem/GHI
  • Emblem/Hip
  • Empire Blue Cross Blue Shield Healthplus
  • Empire Blue Cross/Blue Shield
  • Fidelis Care
  • Healthfirst
  • Healthspring (Cigna Medicare)
  • Local 1199
  • Magnacare (National)
  • Medicare
  • Multiplan
  • MVP Health Care
  • UnitedHealthcare
  • VNSNY CHOICE
  • Wellcare
  • World Trade Center Health Plan

Medical Specialties

Dr. Susan E. Bates has the following 3 specialties

Specialty Expertise

Dr. Susan E. Bates has the following 14 areas of expertise

  • Breast Cancer
  • Cancer
  • Cancerous Tumor
  • Chemotherapy
  • Chromosome Aberrations
  • Colon Cancer
  • Developmental Disorders
  • Internal Medicine
  • Kidney Cancer
  • Lymphoma
  • Metastasis
  • Neoplastic Cell Transformation
  • Oncologist
  • Ovarian Cancer

Certifications, License, & Education

48 Years Experience

MEDICAL LICENSE

Medical Doctor, New York, 2026, Active

EDUCATION & TRAINING

Medical School

University Of Arkansas For Medical Sciences College Of MedicineGraduated in 1978

Other Providers at NewYork-Presbyterian

Frequently Asked Questions

Is Dr. Susan Bates accepting new patients?
Dr. Susan Bates is accepting new patients on Vitals. View Dr. Susan Bates's profile on Vitals to make an appointment.
Does Dr. Susan Bates accept my insurance?
You can see the insurance plans that Dr. Susan Bates accepts on their Vitals profile.
Which hospitals is Dr. Susan Bates affiliated with?
Dr. Susan Bates is affiliated with Newyork Presbyterian Columbia University Irving Medical Center.
Where is Dr. Susan Bates's office located?
Dr. Susan Bates's office is located at 161 Fort Washington Ave # 9, New York, NY, 10032.
Does Dr. Susan Bates accept virtual/telehealth appointments?
Yes, Dr. Susan Bates accepts virtual/telehealth appointments. Click the virtual visit button on their Vitals profile.

Ensuring Data Transparency and Trust: A Guide to Vitals Doctor Listings and Reviews

Our provider data is gathered directly from physicians and publicly available databases. Providers who verify their profiles gain the ability to update information, offering additional details about their specialties,education, treated conditions, performed procedures, and accepted insurances.

Reviews on Vitals are submitted by users only. Recognizing the valuable insights these reviews offer into a doctor's reputation, we maintain internal policies and protocols to ensure the quality and accuracy of all reviews. Importantly, providers cannot delete or alter reviews independently. Reviews can only be deleted or changed following an internal assessment by our customer service team.

Your feedback is highly valued and we encourage you to contact our support team should you encounter any issues.